Biopharmaceutical company Insmed Incorporated (Nasdaq:INSM) disclosed on Tuesday that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.

Insmed noted that brensocatib was well tolerated, with no new safety signals identified, including in the 40 mg arm, which is the highest dose the company has studied to date. Insmed will discontinue its development programme of brensocatib in HS, and intends to present these data at a future congress.

CEDAR was a randomised, double-blind, placebo-controlled, Phase 2b study to evaluate the efficacy and safety of brensocatib in adults with moderate to severe hidradenitis suppurativa. The study enrolled 214 patients at 72 sites globally. In the study, participants were randomised 1:1:1 to receive brensocatib 10 mg, brensocatib 40 mg, or placebo, once daily for 16 weeks. After the first 16 weeks, participants either continued the same randomised dose of brensocatib, or if on placebo, were randomised to receive brensocatib 10 mg or 40 mg. The primary endpoint was percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16.

At Week 16, study participants experienced a 45.5% and 40.3% reduction from baseline in total abscess and inflammatory nodule (AN) count in the brensocatib 10 mg and 40 mg arms, respectively, compared to a 57.1% reduction in the placebo arm.